Monday 24 Jun, 2024 11:20 AM
Site map | Locate Us | Login
   Ujjivan SFB slumps after trimming FY25 loan growth guidance by 500 bps    Volumes jump at Bajaj Holdings & Investment Ltd counter    Hero MotoCorp hikes prices of motorcycles and scooters    Lupin gains on receiving EIR from USFDA for New Jersey facility    MAS Financial gains on raising Rs 500 crore via QIP    Welspun Specialty spurts after emerging as L1 bidder for thermal power project    Capital Goods shares gain    Consumer Durables shares rise    FMCG shares gain    Cipla slides as Goa facility gets 6 USFDA observations    RVNL hits life high on emerging as L-1 bidder for Rs 191-cr railway project    Biocon's new monoclonal antibodies facility in India get manufacturing approval from EMA    Sky Gold hits record high on acquiring Starmangalsutra & Sparkling Chains    DLF Ltd Slides 2.1%, BSE Realty index Shed 1.28%    Bombay Burmah Trading Corporation Ltd Spurts 3.57% 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
NSE SME Quest Laboratories jumps on debut
23-May-24   11:19 Hrs IST

The scrip was listed at Rs 155.10, a premium of 59.90% compared with the initial public offer (IPO) price. The stock is currently frozen in its lower limit of 5% over its listing price.

The counter hit a high of Rs 159 and a low of Rs 147.35. About 14.18 lakh shares of the company changed hands at the counter.

Quest Laboratories' IPO was subscribed 57.26 times. The issue opened for bidding on 15 May 2024 and it closed on 17 May 2024. The price band of the IPO was fixed between Rs 93 to Rs 97 per share.

The IPO comprised fresh issue of 44,49,600 equity shares. The promoter and promoter group shareholding diluted to 65.82% from 90.36% pre-IPO.

The company intends to utilise the net proceeds to meet working capital requirements of the company, for funding of capital expenditure towards purchase of plant and machineries for expansion at the existing manufacturing facility situated at Dhar, Madhya Pradesh and general corporate purposes.

Ahead of the IPO, Quest Laboratories on 14 May 2024, raised Rs 11.98 crore from anchor investors. The board allotted 12.36 lakh shares at Rs 97 per share to 4 anchor investors.

Quest Laboratories engaged in the business of manufacturing of pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. These formulations fall under the trademark ?Quest Laboratories?. The company produces a variety of products, comprising ethical drugs, generic drugs, and over the-counter drugs (OTC). These products are available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids. As of 31 December 2023, the company has 83 employees.

The company recorded revenue from operations of Rs 62.07 crore and net profit of Rs 7.74 crore for the period as on 31 December 2023.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 33425043
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd